Verve Therapeutics, Inc.
Verve Therapeutics, Inc.（VERV）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
verv · 股价预测 · 13 位分析师（近3月）· FMP · 更新于 2025年11月10日
分析师评级与共识
基于过去 3 个月内 13 位华尔街分析师
Hold
13 位分析师
共识
评级分布
12 个月目标价
High
$30.00
Consensus
$18.00
+61.7% upside
Low
$13.00
Median: $14.5 · Last Close: $11.13
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
Consensus Target
$18.00
61.7% upside
High Target
$30
169.5%
Low Target
$13
16.8%
Current Price
$11.13
as of today
Based on analyst price targets, the VERV stock price prediction for the next 12 months ranges from $13 to $30. The consensus VERV price forecast of $18.00 implies 61.7% upside from the current price of $11.13.
短期股价预测
算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $11.09 | ↓ 0.35% |
1-day model range: $11.08–$11.1. Peak: $11.1 (-0.35%).
长期股价预测
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · VERV · Jun 9, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-06-27 | BMO Capital | Downgrade ↓ | Outperform→Market Perform |
| 2025-06-18 | LifeSci Capital | Downgrade ↓ | Outperform→Market Perform |
| 2025-06-18 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2025-06-18 | Jefferies | Downgrade ↓ | Buy→Hold |
| 2025-06-17 | Canaccord Genuity | Downgrade ↓ | Buy→Hold |
| 2025-06-17 | William Blair | Downgrade ↓ | Outperform→Market Perform |
| 2025-04-15 | Canaccord Genuity | Maintains | Buy→Buy |
| 2025-04-15 | Guggenheim | Maintains | Buy→Buy |
| 2025-04-15 | William Blair | Maintains | Outperform→Outperform |
| 2025-04-15 | Cantor Fitzgerald | Upgrade ↑ | Neutral→Overweight |
Wall Street analysts have recently issued updated ratings on Verve Therapeutics, Inc. (VERV) stock. Of the recent 44 rating actions, 2 were upgrades and 6 were downgrades. 13 analysts currently cover VERV.
分析师推荐趋势
VERV analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 3 to 0 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$45M
↑ 200.3% YoY
Revenue Next Year
$16M
↓ 64.3% YoY
EPS This Year
$-2.51
EPS Next Year
$-3.11
↑ 23.6% YoY
EPS ForecastReported vs Estimated
Analysts forecast VERV EPS of $-2.51 for the current fiscal year, based on estimates from 5 analysts. The VERV revenue forecast is $45M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
VERV 股价预测由两类独立数据源支撑：来自 13 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。VERV 的共识目标价为 $18.00（+61.7% 上行空间），分析师共识为 Hold。
VERV 的短期预测（明日）为 $11.09（-0.35%）。
Verve Therapeutics, Inc. 在 NASDAQ 上市，代码 VERV。VERV 在 2027 年的整体展望偏中性/分化，在覆盖分析师中约 31% 对应 Hold 共识。
常见问题
VERV 预测 · 8 个问题根据 13 位华尔街分析师，VERV 的 12 个月平均目标价为 $18.00，最高 $30.00、最低 $13.00。若有图表，中位目标价可在上方查看。相对当前价 $11.13，隐含约 +61.7% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.